The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
31 | 63 | 21 | 75 |
Growth
|
91 | 79 | 65 | 59 |
Safety
|
6 | 11 | 18 | 11 |
Sentiment
|
80 | 68 | 56 | 22 |
|
50 | 55 | 25 | 30 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Analyst Opinions
|
97 | 100 | 92 | 85 |
Opinions Change
|
82 | 36 | 50 | 50 |
Pro Holdings
|
n/a | 57 | 31 | 10 |
Market Pulse
|
46 | 47 | 27 | 22 |
Sentiment
|
80 | 68 | 56 | 22 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
31 | 63 | 21 | 75 |
Growth
|
91 | 79 | 65 | 59 |
|
6 | 11 | 18 | 11 |
Combined
|
25 | 50 | 9 | 41 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Price vs. Sales (P/S)
|
12 | 24 | 24 | 24 |
Price vs. Earnings (P/E)
|
36 | 43 | 67 | 56 |
Price vs. Book (P/B)
|
97 | 97 | 1 | 100 |
Dividend Yield
|
1 | 1 | 1 | 1 |
Value
|
31 | 63 | 21 | 75 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue Growth
|
80 | 78 | 76 | 97 |
Profit Growth
|
88 | 34 | 63 | 32 |
Capital Growth
|
8 | 81 | 10 | 70 |
Stock Returns
|
99 | 75 | 87 | 17 |
Growth
|
91 | 79 | 65 | 59 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Leverage
|
3 | 5 | 9 | 21 |
Refinancing
|
33 | 32 | 55 | 57 |
Liquidity
|
34 | 31 | 29 | 13 |
|
6 | 11 | 18 | 11 |
Discover high‑ranked alternatives to Xeris Pharmaceuticals and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.